The Department of Labor has moved its rescission of the 2013 Home Care Rule to the final rule stage. Here is what a change to caregiver overtime would do to a home care agency P and L, why your state may make it irrelevant, and how buyers price an unresolved rule.
Read more
In behavioral health, buyers are purchasing a stack of licences, accreditations, and payer contracts. What survives a change of ownership, and what that does to your valuation in 2026.
Read more
Payer mix is doing more to set home care agency value in 2026 than size or census. What private pay, Medicaid concentration, and the rules now in force do to your number.
Read more
Four kinds of buyers acquire hospice agencies in 2026. Here is who they are, what each pays, and how the FY2027 CMS final rule changes what they see in diligence.
Read more
The CY2027 Medicare rule keeps margins tight. Exit planning is how home health owners raise value and reduce buyer risk in the 12 to 36 months before a sale.
Read more
The market has reset and buyers are choosier. Here is the six-factor scorecard they use, current home health multiples, and how to raise your agency’s value before a sale.
Read more
Wondering when to sell a home health agency? This 2026 timing guide covers the CMS CY 2027 proposed rule, firming M&A demand, current valuation multiples, and how to read your own readiness.
Read moreArizona is the center of the hospice crackdown. See how the CMS moratorium and the 36-month rule affect selling, what your hospice is worth, and how to prepare.
Read more
Private equity is buying home health agencies again, but on stricter terms. See what buyers underwrite in 2026, the multiples in play, and how to prepare.
Read more
As of June 2026, most home health agencies trade between 6–8x EBITDA. The 2026 CMS rule reset buyer add-back tolerance and widened the valuation gap between diversified and single-payer shops.
Read more